Meta-analysis of clinical impact of onasemnogene abeparvovec treatment of spinal muscular atrophy patients

被引：0
|
作者：
Reyna, S. [1 ]
Dabbous, O. [1 ]
Wallach, S. [1 ]
Patel, A. [1 ]
Toro, W. [1 ]
Ritter, S. [1 ]
机构：
[1] Novartis Gene Therapies Inc, Bannockburn, IL USA
来源：
NEUROMUSCULAR DISORDERS | 2024年 / 43卷
关键词：
D O I：
10.1016/j.nmd.2024.07.608
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
164P
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Matching-adjusted indirect treatment comparison of onasemnogene abeparvovec and nusinersen for the treatment of symptomatic patients with spinal muscular atrophy type 1
    Bischof, Matthias
    Lorenzi, Maria
    Lee, Jennifer
    Druyts, Eric
    Balijepalli, Chakrapani
    Dabbous, Omar
    CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (10) : 1719 - 1730
  • [42] Onasemnogene abeparvovec gene replacement therapy for the treatment of spinal muscular atrophy: a real-world observational study
    Ilaria Bitetti
    Valentina Lanzara
    Giovanna Margiotta
    Antonio Varone
    Gene Therapy, 2023, 30 : 592 - 597
  • [43] Onasemnogene Abeparvovec for Presymptomatic Infants with Spinal Muscular Atrophy and Two Copies of SMN2
    Strauss, Kevin
    Muntoni, Francesco
    Farrar, Michelle
    Saito, Kayoko
    Mendell, Jerry
    Servals, Laurent
    McMillan, Hugh
    Finkel, Richard
    Swoboda, Kathryn
    Kwon, Jennifer
    Zaidman, Craig
    Chiriboga, Claudia
    Iannaccone, Susan
    Krueger, Jena
    Parsons, Julie
    Shieh, Perry
    Kavanagh, Sarah
    Chand, Deepa
    Tauscher-Wisniewski, Sitra
    McGill, Bryan
    Macek, Thomas
    NEUROLOGY, 2022, 98 (18)
  • [44] Respiratory outcomes of onasemnogene abeparvovec treatment for spinal muscular atrophy: national real-world cohort study
    Moran Lavie
    Mika Rochman
    Keren Armoni Domany
    Inbal Golan Tripto
    Moria Be’er
    Omri Besor
    Liora Sagi
    Sharon Aharoni
    Mira Ginsberg
    Iris Noyman
    Hagit Levine
    European Journal of Pediatrics, 184 (1)
  • [45] Onasemnogene abeparvovec gene replacement therapy for the treatment of spinal muscular atrophy: a real-world observational study
    Bitetti, Ilaria
    Lanzara, Valentina
    Margiotta, Giovanna
    Varone, Antonio
    GENE THERAPY, 2023, 30 (7-8) : 592 - 597
  • [46] Comprehensive analysis of adverse events associated with onasemnogene abeparvovec (Zolgensma) in spinal muscular atrophy patients: insights from FAERS database
    Zhang, Wenwen
    Yin, Yizhen
    Yang, Dan
    Liu, Mengyuan
    Ye, Caixia
    Yan, Ruiling
    Li, Ruiman
    FRONTIERS IN PHARMACOLOGY, 2025, 15
  • [47] SOCIETAL COSTS OF SPINAL MUSCULAR ATROPHY TYPE 1 FOR PATIENTS TREATED WITH ONASEMNOGENE ABEPARVOVEC OR NUSINERSEN IN THE UNITED KINGDOM
    Kleintjens, J.
    Patel, A.
    van Keep, M.
    Srivastava, K.
    McHale, P.
    Affinito, S.
    Bischof, M.
    VALUE IN HEALTH, 2024, 27 (06) : S135 - S135
  • [48] Real-world assessment of onasemnogene abeparvovec treatment in patients with spinal muscular atrophy: RESTORE/post-marketing surveillance in Japan
    Saito, K.
    Nagao, R.
    Tsuchida, K.
    Teshima, R.
    Kawase, K.
    NEUROMUSCULAR DISORDERS, 2022, 32 : S92 - S93
  • [49] Acute Benign Myositis Following Onasemnogene Abeparvovec Therapy in Type 1 Spinal Muscular Atrophy
    Dosi, Claudia
    Tozzo, Alessandra
    Masson, Riccardo
    PEDIATRIC NEUROLOGY, 2022, 131 : 23 - 24
  • [50] Outcomes of Children Treated With Nusinersen/Onasemnogene Abeparvovec for Pediatric Spinal Muscular Atrophy Type 1
    Chacko, A.
    Sly, P. D.
    Gauld, L.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
12345